Statins have beneficial effects on platelet free radical activity and intracellular distribution of GTPases in hyperlipidaemia

Clinical Science

Volumn 118, Issue 5, 2010, Pages 359-366

  Hamilton, Paul K ^a   Hughes, Sinead M T ^a   Plumb, Richard D ^a   Devine, Adrian ^a   Leahey, William ^a   Lyons, Kristopher S ^a   Johnston, Dennis ^a   McVeigh, Gary E ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

GTPase; Hyperlipidaemia; Isoprenoid; Nitric oxide; Platelet; Statin; Superoxide radical

Indexed keywords

ATORVASTATIN; FREE RADICAL; GUANOSINE TRIPHOSPHATASE; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; NITRIC OXIDE; PLACEBO; RAC PROTEIN; RHO FACTOR; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CELL MEMBRANE; CELLULAR DISTRIBUTION; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DENSITOMETRY; DRUG DOSE INCREASE; DRUG EFFICACY; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME SYNTHESIS; FEMALE; HUMAN; HYPERLIPIDEMIA; MALE; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DETERMINATION; PROTEIN LOCALIZATION; THROMBOCYTE MEMBRANE; THROMBOCYTE RELEASE REACTION; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; WESTERN BLOTTING;

ADULT; AGED; BLOOD PLATELETS; DOUBLE-BLIND METHOD; FREE RADICALS; GTP PHOSPHOHYDROLASES; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; MIDDLE AGED; NITRIC OXIDE; PYRROLES; RAC GTP-BINDING PROTEINS; RHO GTP-BINDING PROTEINS; SUPEROXIDES;

EID: 71449105935     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/CS20090388     Document Type: Article

References (30)

1. Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., MacFarlane, P. W., McKillop, J. H. and Packard, C. J. (1995) Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N. Eng. J. Med. 333, 1301-1307
2. Scandinavian Simvastatin Survival Study group (1994) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 344, 1383-1389
3. Williams, J. K., Sukhova, G. K., Herrington, D. M. and Libby, P. (1998) Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys. J. Am. Coll. Cardiol. 31, 684-691
4. Endres, M., Laufs, U., Huang, Z., Nakamura, T., Huang, P., Moskowitz, M. A. and Liao, J. K. (1998) Stroke protection by 3-hydroxy-3-methylglutaryl (HMG) CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc. Natl. Acad. Sci. U.S.A. 95 8880-8885
5. Wagner, A. H., Kohler, T., Ruckschloss, U., Just, I. and Hecker, M. (2000) Improvement of nitric-oxide dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation. Arterioscler. Thromb. Vasc. Biol. 20, 61-69
6. Dixon, L. J., Morgan, D. R., Hughes, S. M., McGrath, L. T., El-Sherbeeny, N. A., Plumb, R. D., Devine, A., Leahey, W., Johnston, G. D. and McVeigh, G. E. (2003) Functional consequences of endothelial nitric oxide synthase uncoupling in congestive cardiac failure. Circulation 107, 1725-1728
7. O'Driscoll, G., Green, D. and Taylor, R. R. (1997) Simvastatin, an HMG CoA reductase inhibitor, improves endothelial dysfunction within 1 month. Circulation 95, 1126-1131
8. Libby, P., Ridker, P. M. andMaseri, A. (2002) Inflammation and atherosclerosis. Circulation 105, 1135-1143
9. Goldstein, J. L. and Brown, M. S. (1990) Regulation of the mevalonate pathway. Nature 343, 425-430
10. Liao, J. K. (2002) Isoprenoids as mediators of the biological effects of statins. J. Clin. Invest. 110, 285-288
11. Hall, A. (1998) Rho GTPases and the actin cytoskeleton. Science 279, 509-514
12. Laufs, U. and Liao, J. K. (1998) Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J. Biol. Chem. 273, 24266-24271
13. Wassmann, S., Laufs, U., Baumer, A. T., Muller, K., Konkol, C., Sauer, H., Bohm, M. and Nickenig, G. (2001) Inhibition of geranylgeranylation reduces angiotensin II-mediated free radical production in vascular smooth muscle cells: involvement of angiotensin AT1 receptor expression and Rac1 GTPase. Mol. Pharmacol. 59, 646-654
14. Plumb, R. D., El-Sherbeeny, N. A., Dixon, L. J., Hughes, S. M., Devine, A. B., Leahey, W. J. and McVeigh, G. E. (2005) NAD(P)H-dependent superoxide production in platelets: the role of angiotensin II and protein kinase C. Clin. Biochem. 38, 607-613
15. McVeigh, G. E., Hamilton, P.,Wilson, M., Hanratty, C. G., Leahey, W. J., Devine, A. B., Morgan, D. G., Dixon, L. J. and McGrath, L. T. (2002) Platelet nitric oxide and superoxide release during the development of nitrate tolerance: effect of supplemental ascorbate. Circulation 106, 208-213
16. Shibuki, K. (1990) An electrochemical microprobe for detecting nitric oxide release in brain tissue. Neurosci. Res. 9, 69-76
17. Ichimori, K., Ishida, H., Fukahori, M., Makazawa, H. and Murakami, E. (1994) Practical nitric oxide measurement employing a nitric oxide selective electrode. Rev. Sci. Instrum. 65, 1-5
18. Gyllenhamer, H. (1987) Lucigenin chemiluminescence in the assessment of neutrophil superoxide production. J. Immunol. Methods 97, 209-213
19. Skatchov, M. P., Sperling, D., Hink, U., Mulsch, A., Harrison, D. G., Sindermann, I., Meinertz, T. and Munzel, T. (1999) Validation of Lucigenin as a chemilunimescent probe to monitor vascular superoxide as well as basal vascular nitric oxide production. Biochem. Biophys. Res. Commun. 254, 319-324
20. q family couple the bradykinin receptor to the release of endothelial-derived relaxing factor. J. Clin. Invest. 92, 2168-2172
21. Kaneta, S., Satoh, K., Kano, S., Kanda, M. and Ichihara, K. (2003) All hydrophobic HMG-CoA reductase inhibitors induce apoptotic death in rat pulmonary vein endothelial cells. Atherosclerosis 170, 237-224
22. Ohara, Y., Peterson, T. E. and Harrison, D. G. (1993) Hypercholesterolaemia increases endothelial superoxide anion production. J. Clin. Invest. 91, 2546-2551
23. Radomski, M. W., Palmer, R. M. J. and Moncada, S. (1990) An l-arginine/ nitric oxide pathway present in human platelets regulates aggregation. Proc. Natl. Acad. Sci. U.S.A. 87, 5193-5197
24. Chen, L. Y. and Mehta, J. L. (1996) Further evidence of the presence of constitutive and inducible nitric oxide synthase isoforms in human platelet. J. Cardiovasc. Pharmacol. 27, 154-158
25. Ikeda, H., Takajo, Y. and Murohara, T. (2000) Platelet-derived nitric oxide and coronary risk factors. Hypertension 35, 904-907
26. Freedman, J. E., Loscalzo, J., Barnard, M. R., Alpert, C., Kearney, J. F. and Michelson, A. D. (1997) Nitric oxide released from activated platelets inhibits platelet recruitment. J. Clin. Invest. 100, 350-356
27. Laufs, U., La Fata, V. O., Plutsky, J. and Liao, J. K. (1998) Up-regulation of endothelial nitric oxide synthase by HMG-CoA reductase inhibitors. Circulation 97, 1129-1135
28. Tannous, M., Cheung, R., Vignini, A. and Mutus, B. (1999) Atorvastatin increases ecNOS levels in human platelets of hyperlipidaemic subjects. Thromb. Haemostasis 82, 1390-1394
29. Rueckschloss, U., Galle, J., Holtz, J. and Morawietz, H. (2001) Induction of NAD(P)H oxidase by oxidised low-density lipoprotein in human endothelial cells: Antioxidative potential of hydroxymethylglutaryl coenzyme A reductase inhibitor therapy. Circulation 104, 1767-1772
30. Landmesser, U., Bahlmann, F., Mueller, M., Spiekermann, S., Kirchhoff, N., Schulz, S., Manes, C., Fischer, D., de Groot, K., Fliser, D. et al. (2005) Simvastatin versus Ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans. Circulation 111, 2356-2363